Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Clal Biotechnology Industries
Tel Aviv, Tel Aviv, Israel
- Ownership
- Private
- Development stage
- Other
01
Overview
Clal Biotechnology Industries is an investment holding company; its portfolio includes assets in diverse clinical stages, notably Phase 3 for diabetes (DiaPep277, now exited), later-stage cancer immunotherapy, and commercial-stage wound care (MediWound)[2][9].
- Therapeutic areas
- ImmunologyEndocrinologyRare DiseasesDermatologyOncology
- Modalities
- Small moleculePeptidesCell therapyGene therapymRNA-based drugsAntibodyBiologicDeviceAI-powered diagnostics
- Industry
- Investors
02
Partnerships
Hyperion TherapeuticsBioNTech (via Neon Therapeutics exit and share swap)[6]Genentech, Eli Lilly, Sanofi, Pfizer (via portfolio collaborations)[6]
Beyond the preview
Go deeper on Clal Biotechnology Industries.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Clal Biotechnology Industries.